M&A and equity raisings

6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

US deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

76 deals · US$54bndisclosed · Life Sciences · Clear

Columns
M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Apr 2024 Model N –Vista Equity PartnersAcquisitionCompleted1,250.0Vertical SaaS+1 Jefferies (sell-side)Fenwick & West (sell-side)Kirkland & Ellis (buy-side)William Blair (buy-side)
Dec 2024 Randlab Group –Animalcare GroupAcquisitionCompleted74.3Healthcare+1 Squire Patton Boggs (buy-side)Pitcher Partners (buy-side)
Jan 2025 ImaginAb therapeutic candidates, biologics technology platform and research facility ImaginAbTelix PharmaceuticalsAsset saleCompleted45.0Healthcare+1 Jefferies (sell-side)Stifel (sell-side)
Feb 2025 AdvanCell –SV Health InvestorsStakeCompleted–Healthcare+1 Johnson Winter Slattery (buy-side)Honigman (buy-side)
Feb 2025 Mayne Pharma Group –Cosette PharmaceuticalsSchemeWithdrawn417.9Healthcare+1 Jefferies (sell-side)Gilbert + Tobin (sell-side)Arnold & Porter (sell-side)Davis Wright Tremaine (sell-side)EY (sell-side)Deloitte (sell-side)Santander (buy-side)UBS (buy-side)Corrs Chambers Westgarth (buy-side)Ropes & Gray (buy-side)
Jun 2025 InVetro –Animalcare GroupStakeAnnounced–Healthcare+1 Squire Patton Boggs (buy-side)
Jul 2025 BD Biosciences & Diagnostic Solutions business Becton, Dickinson and CompanyWatersAsset saleCompleted18,800.0Life Sciences+2 Citi (sell-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Barclays (buy-side)Kirkland & Ellis (buy-side)
Aug 2025 DBG Global Enterprises –BDT & MSD PartnersStakeAnnounced1,039.4Healthcare+1 MinterEllison (sell-side)
Aug 2025 DBG Health –BDT & MSD PartnersStakeCompleted1,039.4Healthcare+1 MinterEllison (sell-side)Allens (buy-side)Sidley Austin (buy-side)
Oct 2025 SWK Holdings –Runway Growth Finance Corp.AcquisitionCompleted249.0Financial Services+1 Keefe, Bruyette & Woods (sell-side)Goodwin (sell-side)Kroll (sell-side)Simpson Thacher & Bartlett (buy-side)Dechert (buy-side)
Oct 2025 Sedarex –BiotronAcquisitionCompleted1.0Healthcare+1 Peak Asset Management (buy-side)
Dec 2025 Freenome Holdings –Perceptive Capital Solutions CorpMergerCompleted725.0Diagnostics+2 TD Securities (sell-side)Guggenheim Securities (sell-side)BTIG (sell-side)Goodwin (sell-side)Greenberg Traurig (sell-side)Richards, Layton & Finger (sell-side)H.C. Wainwright & Co. (sell-side)Jefferies (buy-side)Leerink Partners (buy-side)Cooley (buy-side)Ropes & Gray (buy-side)Maples Group (buy-side)Ogier (buy-side)Scalar (buy-side)
Dec 2025 Generation Bio Co. –XRA 7 Corp.AcquisitionAnnounced–Biotech+1 TD Securities (sell-side)WilmerHale (sell-side)Gibson Dunn (buy-side)
Jan 2026 BioRender –Dimension CapitalStakeAnnounced900.0Software+2 Sidley Austin (sell-side)
Jan 2026 PTC Therapeutics' remaining royalty on Roche's Evrysdi PTC TherapeuticsRoyalty PharmaAsset saleAnnounced240.0Specialty finance and leasing+2 Goodwin (buy-side)
Jan 2026 Evidinno Outcomes Research –United BioSourceAcquisitionCompleted–Pharma Services+2 Fairmount Partners (sell-side)
Jan 2026 Aktana –PharmaForceIQAsset saleAnnounced–Healthcare Software+2 Canaccord Genuity
Jan 2026 Verana Health ––MergerAnnounced–Healthcare Software+2 BofA Securities (sell-side)Wilson Sonsini Goodrich & Rosati (buy-side)
Jan 2026 Cannatrek –Little Green PharmaSchemeCompleted–Healthcare+1 K&L Gates (sell-side)Intrinsic Partners (sell-side)RSM (sell-side)Hamilton Locke (buy-side)Canaccord Genuity (buy-side)
Jan 2026 Ganymede –Apprentice.ioAcquisitionAnnounced–Software+1 Cooley (buy-side)
Jan 2026 StarLIMS –Turn/River CapitalStakeAnnounced–Software+2
Feb 2026 Dutscher Group –Vivo CapitalAcquisitionAnnounced–Life Sciences+1 Sidley Austin (buy-side)Mayer Brown (buy-side)
Feb 2026 Bruder Consulting & Venture Group –Dark Horse Consulting GroupAcquisitionCompleted–Accounting, legal and consulting+1 Goodwin (sell-side)Edgemont Partners (sell-side)
Feb 2026 Laysan Bio –Gannet BioChemAcquisitionAnnounced–Pharma Services+2 Goodwin (buy-side)
Mar 2026 Lonza Capsules & Health Ingredients division Lonza Group AGLone Star FundsAsset saleAnnounced–Pharmaceutical Manufacturing+2 Kirkland & Ellis (buy-side)
Mar 2026 JSR Life Sciences chromatography business JSR Life SciencesMERCK KGaAAsset saleCompleted–Life Sciences+1 William Blair
Mar 2026 UK Biocentre –Azenta UKAcquisitionCompleted26.9Life Sciences+1 Deloitte (buy-side)Bird & Bird (buy-side)
Mar 2026 Biocare Medical –Agilent TechnologiesAcquisitionAnnounced950.0Diagnostics+1 Sullivan & Cromwell (buy-side)
Mar 2026 Stratis Group –Nexus HealthAcquisitionAnnounced–Accounting, legal and consulting+1 Clearsight Advisors (sell-side)Pillsbury Winthrop Shaw Pittman (sell-side)
Apr 2026 Thermo Fisher Scientific's microbiology division Thermo Fisher ScientificAstorgAsset saleAnnounced1,075.0Diagnostics+1 Cravath, Swaine & Moore (sell-side)Perella Weinberg Partners (sell-side)Latham & Watkins (buy-side)Moelis & Company (buy-side)
Apr 2026 Accessus Health shareholders of Ecker + Ecker and Accessus HealthAthagorasAcquisitionAnnounced–Accounting, legal and consulting+2 Latham & Watkins (sell-side)
Apr 2026 TriNetX –Regeneron PharmaceuticalsStakeCompleted–Healthcare Software+2 William Blair
Apr 2026 Celerion H.I.G. Capital affiliateTHL PartnersAcquisitionAnnounced–Pharma Services+2 LazardKirkland & Ellis (buy-side)Paul, Weiss (buy-side)
Apr 2026 EpiVax –SV Health InvestorsAcquisitionAnnounced–Pharma Services+2 Morgan Lewis (buy-side)
Apr 2026 Certara Regulatory and Medical Writing business CertaraVeristatAsset saleAnnounced135.0Pharma Services+1 Perella Weinberg Partners (sell-side)Troutman Pepper Locke (sell-side)Guggenheim Securities (buy-side)McDermott Will & Schulte (buy-side)
Apr 2026 XOMA Royalty –Ligand PharmaceuticalsAcquisitionCompleted739.0Specialty finance and leasing+2 Leerink Partners (sell-side)H.C. Wainwright & Co. (sell-side)Gibson Dunn (sell-side)Stifel (buy-side)Citi (buy-side)Paul Hastings (buy-side)Collected Strategies (buy-side)
May 2026 Regenity Biosciences –CinvenStakeAnnounced–Medtech+1 Baird (sell-side)
May 2026 Beacon Hanson Wade GroupCorten CapitalAcquisitionAnnounced–Market Intelligence+2 Baird (sell-side)
May 2026 Imexpharm SK GroupLian SGP HoldingAcquisitionAnnounced–Healthcare+1 Allens (sell-side)Linklaters (sell-side)
May 2026 Sutter Instrument Corp. –Lafayette InstrumentAcquisitionCompleted–Manufacturing+2 EC M&A (sell-side)Donahue Fitzgerald (sell-side)Akerman (buy-side)RSM (buy-side)
May 2026 Ennov Group –Bregal SagemountStakeAnnounced–Healthcare Software+2 Proskauer RoseGoodwin (buy-side)
Jun 2026 Aspen Pharmacare Asia Pacific business Aspen Pharmacare HoldingsBGH CapitalAcquisitionAnnounced1,632.2Healthcare+1 Allens (buy-side)
Jun 2026 Kalderos –Model NAcquisitionAnnounced–Healthcare Software+2 Kirkland & Ellis (buy-side)
Jun 2026 kneat.com –Thoma Bravo, L.P.AcquisitionPending453.6Vertical SaaS+1 Kirkland & Ellis (buy-side)
Jun 2026 Helio Health Group –WestView Capital PartnersStakeCompleted–AI+1 Latham & Watkins (buy-side)
Jun 2026 Ignite Proteomics AditxtProposed Ignite Proteomics Inc. holding companyMergerPending150.0Life Sciences+2 Ladenburg Thalmann
Jun 2026 Simulations Plus –Affiliates of AltarisAcquisitionAnnounced375.0Life Sciences+2 Morgan Stanley (sell-side)Procopio, Cory, Hargreaves & Savitch (sell-side)Bass, Berry & Sims (buy-side)Truist Securities (buy-side)J.P. Morgan (buy-side)Kirkland & Ellis (buy-side)Latham & Watkins (buy-side)
Jun 2026 Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program Sangamo TherapeuticsEli Lilly and CompanyAsset saleCompleted–Biotech+1 Raymond JamesPaul, Weiss (buy-side)
Jun 2026 Bio-Techne –Merck KGaAAcquisitionPending11,300.0Life Sciences+1 Goldman Sachs (sell-side)Sidley Austin (sell-side)Joele Frank, Wilkinson Brimmer Katcher (sell-side)Guggenheim Securities (buy-side)J.P. Morgan (buy-side)Sullivan & Cromwell (buy-side)
Jul 2026 GBA Group ArdianBridgepointAcquisitionAnnounced–Testing & Inspection+1 Latham & Watkins (buy-side)

Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.